logo
ResearchBunny Logo
A randomized controlled trial of heterologous ChAdOx1 nCoV-19 and recombinant subunit vaccine MVC-COV1901 against COVID-19

Medicine and Health

A randomized controlled trial of heterologous ChAdOx1 nCoV-19 and recombinant subunit vaccine MVC-COV1901 against COVID-19

C. Chen, L. Yang, et al.

This groundbreaking study conducted by Chih-Jung Chen and colleagues explores the immunogenicity and safety of a novel COVID-19 vaccination strategy that combines ChAdOx1 with MVC-COV1901. Discover how this heterologous prime-boost approach significantly enhances antibody responses, particularly against the Delta variant, without serious adverse events.

00:00
00:00
Playback language: English
Abstract
This study investigated the immunogenicity and safety of a heterologous prime-boost COVID-19 vaccination strategy using ChAdOx1 (viral vector) followed by MVC-COV1901 (spike-2P subunit). 100 healthy adults who received a first dose of ChAdOx1 received a booster dose of either ChAdOx1 or MVC-COV1901. The MVC-COV1901 booster resulted in significantly higher neutralizing antibody titers against both the wild-type and Delta variant of SARS-CoV-2 compared to the ChAdOx1 booster. Both B and T cell responses were substantially enhanced by the heterologous schedule, particularly with a shorter prime-boost interval. No serious adverse events were reported.
Publisher
Nature Communications
Published On
Sep 17, 2022
Authors
Chih-Jung Chen, Lan-Yan Yang, Wei-Yang Chang, Yhu-Chering Huang, Cheng-Hsun Chiu, Shin-Ru Shih, Chung-Guei Huang, Kuan-Ying A. Huang
Tags
COVID-19
vaccination
ChAdOx1
MVC-COV1901
immunogenicity
neutralizing antibodies
variant response
Listen, Learn & Level Up
Over 10,000 hours of research content in 25+ fields, available in 12+ languages.
No more digging through PDFs, just hit play and absorb the world's latest research in your language, on your time.
listen to research audio papers with researchbunny